CHARTA Shows Survival Benefit of Four-Drug Regimen for Advanced CRC

Video

This video examines results of the CHARTA trial, which tested first-line FOLFOX plus bevacizumab with or without irinotecan in patients with advanced colorectal cancer.

The CHARTA trial tested FOLFOX plus bevacizumab with or without irinotecan in patients with metastatic colorectal cancer.

In this video, Hans-Joachim Schmoll, MD, PhD, of the Martin Luther University Halle-Wittenberg in Halle, Germany, discusses results of the trial, covering the survival outcomes, subgroup analyses, and quality-of-life data.

The results of CHARTA (abstract 658) were presented at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held January 19–21 in San Francisco.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Related Content